Blog

December 29, 2015

Letter to shareholders

Office of the CEO December 29, 2015 Fellow DigiPath Shareholders: It has been a year of tremendous progress for DigiPath, Inc. In 2015 we successfully opened our first cannabis testing facility, gained an audience of hundreds of thousands for our cannabis media outlet, and restructured our business units to focus entirely on this rapidly expanding industry. We anticipate that we will reap the rewards of our hard work in 2016—the cannabis sector is about to bloom, and we are ready for the harvest. 2015 in Review After many months of intensive planning, we opened the flagship location of our cannabis testing unit, DigiPath Labs, in June. We chose the Las Vegas location because Nevada was developing the nation’s most stringent policies on cannabis safety, and our dedication to reliable, replicable testing results fit perfectly with the State’s goals for patient safety. DigiPath Labs began earning substantive revenue in October, and has now tested more than 250 cannabis flower samples, representing over 1,250 pounds of cured flower from many of the 16 growers now licensed by the State of Nevada. We continue to add new customers as they come online, and work with The Association of Commercial Cannabis Laboratories and the […]
April 13, 2015

Letter to Shareholders

From the Office of the CEO April 13, 2015 Fellow DigiPath Shareholders: We expect to open our first cannabis analytical testing laboratory in just a few short weeks, and it looks like we’ll be one of the first labs to open in Nevada. As we help usher medicinal marijuana into the Silver State, I wanted to update you on the progress we are making across all of our business units. DigiPath Labs Less than a year ago, Dr. Cindy Orser joined DigiPath Labs as our Chief Science Officer out of concern for patient safety. Our goal was to help the legal cannabis industry weed out products that contain potentially unsafe levels of contaminants, such as solvents, pesticides, mold, heavy metals, and microbes. In less than five months since receiving a Nevada State provisional license to build and operate a lab in Clark County, we have assembled an exceptional team of scientists, developed industry-leading processes, and invested over $1 million to construct and equip our flagship cannabis testing facility in Las Vegas. The last remaining hurdle—which is affecting everyone in Nevada—is for state officials to publish the official list of testing requirements, which are under review. Although no deadline has been […]
December 17, 2014

Letter to Shareholders

From the Office of the CEO Fellow DigiPath Shareholders: This is a very exciting time to be involved in the digital pathology and cannabis industries, and as investors in DigiPath, Inc., you and I are stakeholders in both. As co-founder, and now CEO, of DigiPath, Inc., I am always looking to improve things—including how we communicate. I believe healthy relationships are built on frequent and direct communication. As such, I will send these types of updates to you going forward, to keep you abreast of our successes and the progress we are making across all of our operational fronts. Market Growth We are involved in high-growth industries. According to a recent research report published by MarketsandMarkets, the digital global pathology market was estimated to have reached $250.2 million in 2013, and forecasters estimate it to reach $437 million by 2018. This represents a compound annual growth rate of 11.8 percent. The cannabis market is growing faster than the smartphone market. An estimated $1.43 billion worth of legal marijuana was sold in 2013, and $2.34 billion is expected to be sold in 2014. That’s growth of 64 percent—and we’re just getting started. Expansion of cannabis laws in states across the country […]